Search results for " crohn"

showing 10 items of 78 documents

The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy.

2019

BACKGROUND We report a prospective, nationwide cohort evaluating the safety and effectiveness of CT-P13. METHODS A structured database was used to record serious adverse events (SAEs), clinical remission/response, inflammatory biomarkers (CRP and calprotectin), and endoscopic findings. RESULTS Eight hundred ten patients with inflammatory bowel disease (IBD) (452 Crohn's disease [CD]) were enrolled. Four hundred fifty-nine patients were naive to anti-TNFα (group A), 196 had a previous exposure (group B), and the remaining 155 were switched to CT-P13 (group C). All patients were included in the safety evaluation with a mean follow-up of 345 ± 215 days and a total number of 6501 infusions. One…

0301 basic medicineAdultMalemedicine.medical_specialtyAdolescentSettore MED/12 - GASTROENTEROLOGIABiosimilar; Crohn's disease; CT-P13; Inflammatory bowel disease; Inflectra; Infliximab; Remsima; Ulcerative colitis; Adolescent; Adult; Antibodies Monoclonal; Female; Follow-Up Studies; Gastrointestinal Agents; Humans; Inflammatory Bowel Diseases; Infliximab; Italy; Male; Prognosis; Prospective Studies; Young AdultInflectraInflammatory bowel diseaseInflammatory bowel diseaseAntibodies03 medical and health sciencesYoung Adult0302 clinical medicineGastrointestinal AgentsInternal medicineMonoclonalmedicineImmunology and AllergyHumansProspective StudiesRemsimaProspective cohort studyCrohn's diseasebusiness.industryCrohn's disease; ulcerative colitis; inflammatory bowel disease; Infliximab; Remsima; Inflectra; biosimilar; CT-P13BiosimilarSettore MED/09 - MEDICINA INTERNAGastroenterologyAntibodies Monoclonalmedicine.diseaseInflammatory Bowel DiseasesPrognosisUlcerative colitisInfliximabInfliximabCrohn's disease030104 developmental biologyUlcerative colitisItalyCohort030211 gastroenterology & hepatologyFemaleCalprotectinbusinessCT-P13Cohort studymedicine.drugFollow-Up StudiesInflammatory bowel diseases
researchProduct

A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients with Crohn's Di…

2019

Background and aims There is an unmet need to better understand the effectiveness of different biologics in inflammatory bowel diseases. We aimed at performing a multicentre, real-life comparison of the effectiveness of infliximab [IFX] and adalimumab [ADA] in Crohn's disease [CD]. Methods Data of consecutive patients with CD treated with IFX and ADA from January 2013 to May 2017 were extracted from the cohort of the Sicilian Network for Inflammatory Bowel Disease. We used propensity score-matching accounting for the main baseline characteristics in TNF-α inhibitor-naive and non-naive patients. Results A total of 632 patients [735 total treatments] were included. Among naive patients, a cli…

0301 basic medicineAdultMalemedicine.medical_specialtyInflammatory bowel diseaseGastroenterology03 medical and health sciencesYoung Adult0302 clinical medicineCrohn DiseaseGastrointestinal AgentsInternal medicinemedicineAdalimumabHumansYoung adultSicilypropensity scoreCrohn's diseasebusiness.industryTumor Necrosis Factor-alphaGastroenterologyAdalimumabGeneral MedicineOdds ratiomedicine.diseaseAdalimumab; infliximab; propensity score; Adalimumab; Adult; Crohn Disease; Female; Gastrointestinal Agents; Humans; Infliximab; Male; Propensity Score; Sicily; Treatment Outcome; Tumor Necrosis Factor-alpha; Young AdultInfliximab030104 developmental biologyTreatment OutcomeCohortPropensity score matching030211 gastroenterology & hepatologyFemalebusinessinfliximabmedicine.drug
researchProduct

Alternative Splice Forms of CYLD Mediate Ubiquitination of SMAD7 to Prevent TGFB Signaling and Promote Colitis

2018

Background & Aims The CYLD lysine 63 deubiquitinase gene (CYLD) encodes tumor suppressor protein that is mutated in familial cylindromatosus, and variants have been associated with Crohn disease (CD). Splice forms of CYLD that lack exons 7 and 8 regulate transcription factors and functions of immune cells. We examined the expression of splice forms of CYLD in colon tissues from patients with CD and their effects in mice. Methods We performed immunohistochemical analyses of colon tissues from patients with untreated CD and patients without inflammatory bowel diseases (controls). We obtained mice that expressed splice forms of CYLD (sCYLD mice) without or with SMAD7 (sCYLD/SMAD7 mice) from tr…

0301 basic medicineTranscription FactorBiopsyInbred C57BLTransgenicImmune RegulationSettore MED/12MiceRandom Allocation0302 clinical medicineCrohn DiseaseReference ValuesNeedleIntestinal Mucosaintegumentary systemChemistryBiopsy NeedleGastroenterologyT helper cellFlow CytometryPost-translational ModificationImmunohistochemistryDeubiquitinating Enzyme CYLDCysteine Endopeptidasesmedicine.anatomical_structure030211 gastroenterology & hepatologyTumor necrosis factor alphaSignal TransductionGenetically modified mouseRegulatory T cellTransgeneMice TransgenicSmad7 ProteinTransforming Growth Factor beta103 medical and health sciencesImmune systemmedicineAnimalsHumansCytokine SignalingHepatologyAnimalHEK 293 cellsUbiquitinationMolecular biologyMice Inbred C57BLDisease Models Animal030104 developmental biologyDisease ModelsCytokine Signaling; Immune Regulation; Post-translational Modification; Transcription Factor; Biopsy Needle; Crohn Disease; Cysteine Endopeptidases; Deubiquitinating Enzyme CYLD; Disease Models Animal; Flow Cytometry; Immunohistochemistry; Intestinal Mucosa; Mice Inbred C57BL; Mice Transgenic; Random Allocation; Reference Values; Signal Transduction; Smad7 Protein; Transforming Growth Factor beta1; UbiquitinationTransforming growth factorGastroenterology
researchProduct

Splenic Littoral Cell Hemangioendothelioma in a Patient With Crohn's Disease Previously Treated With Immunomodulators and Anti-TNF Agents: A Rare Tum…

2011

Th e risk of malignancy in Crohn ’ s disease (CD) has been well described. Moreover, immunomodulators, uch as azathioprine (AZA) and 6-mercaptopurine (6-MP), and biological agents, such as infl iximab and adalimumab, may promote carcinogenesis ( 1 – 3 ). Splenic littoral cell tumors are recently described tumors of vascular origin composed of endothelial cells, with typical microscopic and immunohistochemical features of splenic sinus lining cells ( 4 ). Clinical findings are not specific, and outcome is unpredictable but usually benign, although a few cases with a malignant behavior have been reported ( 5,6 ). We report a 58-year-old Caucasian man with a long history of ileocolonic CD.

6-MercaptopurineMalePathologymedicine.medical_specialtyColonic Diseasemedicine.medical_treatmentAzathioprineSplenic NeoplasmHemangioendotheliomaHemangiomaImmunosuppressive AgentImmunocompromised HostImmunologic FactorCrohn Disease6-Mercaptopurine; Azathioprine; Colonic Diseases; Crohn Disease; Gastrointestinal Agents; Hemangioendothelioma; Hemangioma; Humans; Ileal Diseases; Immunologic Factors; Immunosuppressive Agents; Male; Middle Aged; Splenic Neoplasms; Tumor Necrosis Factor-alpha; Immunocompromised Host; GastroenterologyAzathioprineGastrointestinal AgentMedicineGastrointestinal agentCrohn's diseaseHepatologyTumor Necrosis Factor-alphabusiness.industryGastroenterologyImmunosuppressionMiddle Agedmedicine.diseaseSplenic NeoplasmHemangioendotheliomaImmunologyIleal DiseaseTumor necrosis factor alphaHemangiomabusinessHumanmedicine.drugAmerican Journal of Gastroenterology
researchProduct

P-POSSUM score: a prognostic instrument for postoperative complications in Crohn's disease

2018

The purpose of this work is to demonstrate the correlation between the p-POSSUM score and the severity of Crohn's Disease (CD) postoperative complications, evaluated by using the Clavien-Dindo score.We have selected data of 22 patients (11 males, 11 females) that had been recovered in the Operative Unit of General Surgery of the University of Palermo General Hospital and undergone surgery for CD from 2010 to 2017.Patients who underwent surgery for complicated CD was divided in three different group on the base of Clavien Dindo score, C1 (Clavien-Dindo ≤ 1), C2 (Clavien Dindo = 2), and C3 (Clavien Dindo ≥ 3). ANOVA one way statistic analysis was used to investigate the presence of statistic …

AdultMaleInternet P-Possum score Crohn’s disease surgery complicationsIleostomyIncidenceMiddle AgedPrognosisRisk AssessmentSeverity of Illness IndexEndoscopy GastrointestinalPostoperative ComplicationsCrohn DiseaseDrainageHumansFemale
researchProduct

IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes

2018

GWAS have identified >200 risk loci for Inflammatory Bowel Disease (IBD). The majority of disease associations are known to be driven by regulatory variants. To identify the putative causative genes that are perturbed by these variants, we generate a large transcriptome data set (nine disease-relevant cell types) and identify 23,650 cis-eQTL. We show that these are determined by ∼9720 regulatory modules, of which ∼3000 operate in multiple tissues and ∼970 on multiple genes. We identify regulatory modules that drive the disease association for 63 of the 200 risk loci, and show that these are enriched in multigenic modules. Based on these analyses, we resequence 45 of the corresponding 100 ca…

AdultMaleMultifactorial InheritanceQUANTITATIVE TRAIT LOCUSGenotypeSEQUENCING DATAQuantitative Trait LociSUSCEPTIBILITYPolymorphism Single NucleotideArticleCohort StudiesCODING VARIANTSCrohn Disease80 and overJournal ArticleMedicine and Health SciencesLOCUSHumansGenetic Predisposition to DiseasePolymorphismGENOME-WIDE ASSOCIATIONGenetic Association StudiesAgedAged 80 and overScience & TechnologyAdult; Aged; Aged 80 and over; Cohort Studies; Crohn Disease; Female; Gene Expression Profiling; Genetic Association Studies; Genetic Predisposition to Disease; Genotype; Humans; Inflammatory Bowel Diseases; Male; Middle Aged; Polymorphism Single Nucleotide; Quantitative Trait Loci; Sequence Analysis DNA; Multifactorial InheritanceGene Expression ProfilingCOMPLEX TRAITSBiology and Life SciencesSequence Analysis DNASingle NucleotideDNAMiddle AgedInflammatory Bowel DiseasesCROHNS-DISEASEMultidisciplinary SciencesQUANTITATIVE TRAITRARE VARIANTSScience & Technology - Other TopicsFemaleLOW-FREQUENCYSequence AnalysisINFLAMMATORY-BOWEL-DISEASE
researchProduct

Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis

2009

Objective Subclinical gut inflammation is common in spondylarthritis, but the immunologic abnormalities underlying this process are undefined. Perturbation of the interleukin-23 (IL-23)/Th17 axis has emerged as a fundamental trigger of chronic inflammation. This study was undertaken to investigate the expression and tissue distribution of IL-23/Th17–related molecules in Crohn's disease (CD) and in subclinical gut inflammation in ankylosing spondylitis (AS). Methods Quantitative gene expression analysis of Th1/Th2 and IL-23/Th17 responses was performed in intestinal biopsy samples obtained from 12 patients with CD, 15 patients with AS, and 13 controls. IL-23 tissue distribution and identific…

AdultMalePaneth Cellschronic inflammationPathologymedicine.medical_specialtyImmunologyGene ExpressionInflammationMonocytesTh2 CellsRheumatologyIntestinal mucosaIleumankylosing spondylitisPrevalencemedicineInterleukin 23HumansImmunology and Allergyinterleukin-23 (IL-23); Th 17;chronic inflammation; Crohn's disease; ankylosing spondylitisSpondylitis AnkylosingPharmacology (medical)IleitisRNA MessengerIntestinal MucosaSpondylitisinterleukin-23 (IL-23)Subclinical infectionAnkylosing spondylitisbusiness.industryInterleukin-17IleitisMiddle AgedTh1 Cellsmedicine.diseaseUp-RegulationCrohn's diseaseSTAT1 Transcription FactorTh 17ImmunologyInterleukin-23 Subunit p19FemaleInterleukin 17medicine.symptombusinessArthritis & Rheumatism
researchProduct

CLINICAL COURSE OF SEVERE COLITIS: A COMPARISON BETWEEN CROHN'S DISEASE AND ULCERATIVE COLITIS.

2018

Few data are available about the clinical course of severe colonic Crohn’s disease (CD). The aim of this study is to describe the clinical course of severe Crohn’s colitis in a patient cohort with isolated colonic or ileocolonic CD, and to compare it with the clinical course of patients with severe ulcerative colitis (UC). Thirty-four patients with severe Crohn’s colitis were prospectively identified in our cohort of 593 consecutive hospitalized patients through evaluation of the Crohn’s Disease Activity Index score and the Harvey-Bradshaw Index. One hundred sixty-nine patients with severe ulcerative colitis were prospectively identified in our cohort of 449 consecutive hospitalized patient…

AdultMaleSettore MED/18 - Chirurgia GeneraleSettore MED/12 - GastroenterologiaCrohn DiseaseHumansColitis UlcerativeFemalecolectomy Crohn's diesease ulcerative colitisMiddle Aged
researchProduct

Infliximab in the treatment of Crohn's disease: Predictors of response in an Italian multicentric open study

2005

Abstract Background. Almost 20% of patients with active Crohn's disease are refractory to conventional therapy. Infliximab is a treatment of proven efficacy in this group of patients and it is not clear which variables predict a good response. Aims. To evaluate the role of infliximab looking at the predictors of response in a large series of patients with Crohn's disease. Patients and methods. Five hundred and seventy-three patients with luminal refractory Crohn's disease (Crohn's Disease Activity Index (CDAI) > 220–400) (312 patients) or with fistulising disease (190 patients) or both of them (71 patients) were treated with a dose of 5 mg/kg in 12 Italian referral centres. The primary endp…

AdultMalemedicine.medical_specialtyFistulaPredictors of responseAge at diagnosisDiseaseGastroenterologyAntibodiesDose-Response RelationshipCrohn DiseaseGastrointestinal AgentsRefractoryInternal medicineMonoclonalmedicineHumansinfliximab.crohn's disease.Settore MED/12 - GastroenterologiaCrohn's diseaseDose-Response Relationship DrugHepatologybusiness.industryRemission InductionSmokingGastroenterologyAntibodies Monoclonalmedicine.diseaseCrohn's Disease Activity IndexInfliximabInfliximabSurgeryOpen studyCrohn's diseaseCrohn's disease; Infliximab; Predictors of response; Adult; Antibodies Monoclonal; Crohn Disease; Dose-Response Relationship Drug; Female; Fistula; Gastrointestinal Agents; Humans; Infliximab; Italy; Male; Multivariate Analysis; Remission Induction; SmokingItalyConcomitantMultivariate AnalysisFemaleCrohn's disease; Infliximab; Predictors of responseDrugbusinessmedicine.drugDigestive and Liver Disease
researchProduct

Laparoscopic ileocecal resection in acute and chronic presentations of Crohn's disease. A single center experience

2017

Introduction The terminal ileum is the most involved tract in Crohn's disease. The obstruction in this location is the most frequent complication. Acute or chronic presentations can occur. Surgery finds a role in the management of chronic strictures and in acute clinical presentations with complications not improving with conservative therapy. Patients and methods We investigate the outcome of patients with obstruction of the ileo-cecal bowel tract laparoscopically managed. It was analyzed the average operative time (OT), the conversion rate and the occurrence of re-operation due to surgical complications. Results 21 patients underwent an ileocecal resection for complicated Crohn's disease …

AdultMalemedicine.medical_specialtyOperative TimeAnastomotic LeakAnastomosisClinical PracticeHospitals University03 medical and health sciencesIleocecal valve0302 clinical medicineCrohn DiseaseRisk FactorsRetrospective StudiemedicineHumansHemoperitoneumLaparoscopyRetrospective StudiesAcute Disease; Adult; Anastomosis Surgical; Anastomotic Leak; Chronic Disease; Conversion to Open Surgery; Crohn Disease; Female; Hospitals University; Humans; Ileal Diseases; Ileocecal Valve; Intestinal Obstruction; Length of Stay; Male; Operative Time; Retrospective Studies; Risk Factors; Treatment Outcome; LaparoscopyCrohn's diseaseIleocecal Valvemedicine.diagnostic_testbusiness.industryIleal DiseasesGeneral surgeryMortality rateRisk FactorAnastomosis SurgicalRetrospective cohort studyLength of Staymedicine.diseaseConversion to Open SurgerySurgerymedicine.anatomical_structureTreatment Outcome030220 oncology & carcinogenesisAcute DiseaseChronic DiseaseIleal Disease030211 gastroenterology & hepatologyFemaleLaparoscopymedicine.symptombusinessComplicationIntestinal ObstructionHuman
researchProduct